Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
Valeria Dipasquale1, Ugo Cucinotta1, Claudio Romano1
1Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
Biologics : Targets & Therapy
|June 20, 2022
Summary
Biosimilars offer a cost-effective alternative to biologics for inflammatory bowel diseases (IBD). Evidence shows biosimilars are safe and effective in both adults and children with IBD.
Area of Science:
- Gastroenterology
- Pharmacology
- Pediatrics
Background:
- Biologic drugs have transformed chronic disease management, including inflammatory bowel diseases (IBD).
- Biologics are associated with significant direct medical costs.
- Biosimilars offer an affordable alternative as reference biologic patents expire.
Purpose of the Study:
- To review the evidence for biosimilar use in IBD.
- To focus on biosimilar efficacy and safety in pediatric IBD.
- To discuss practical approaches for biosimilar use in pediatric IBD.
Main Methods:
- Systematic review of available evidence.
- Analysis of studies in adult and pediatric IBD populations.
- Examination of clinical data on biosimilar efficacy and safety.
Main Results:
- Growing evidence supports the efficacy and safety of biosimilars in IBD.
- Biosimilars are effective in both treatment-naïve patients and those switching from reference biologics.
- Reassuring data exists for both adult and pediatric IBD patients.
Conclusions:
- Biosimilars are a viable and cost-effective treatment option for IBD.
- Evidence supports the use of biosimilars in pediatric IBD.
- Practical strategies for implementing biosimilars in pediatric care are emerging.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
176
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
176
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
229
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
229
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
404
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
404
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
199
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
199
01:29Drugs for Treatment of Ulcerative Colitis in IBD
235
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
235